PanMediso Holdings has been committed to promoting the research and innovation of isotope nuclear medicine, and continues to pay attention to and support innovative development in the industry. Recently, news about isotope-related innovations has attracted strong attention in the field of nuclear medicine. 1.[ARTBIO announced the completion of an excess Series A financing of more than US$90 million. F-Prime Capital and Omega Funds, the leading institutions in the seed round, also significantly participated in this financing. ] 2.[Ractigen Therapeutics’ RAG-01 became the second saRNA drug in the world to enter the clinical stage and the first saRNA drug in China to achieve this milestone. ] 3. [Lepu Biopharma's independently developed EGFR-targeted ADC product MRG003 has been granted fast track status by the FDA, providing new hope for the treatment of advanced nasopharyngeal cancer (NPC). ] 4. [CARsgen's CT071 received IND approval from the FDA and became a CAR-T cell product candidate for relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia. ] 5. [China National Nuclear Corporation successfully independently developed kilogram-level 99% abundance molybdenum-100 isotope, achieving independent supply of key molybdenum isotope materials in China] PanMediso Holdings keenly grasped that this is a clear signal that the field of isotope nuclear medicine is ushering in a new round of high attention. By continuing to pay attention to market needs, we strive to find and promote more forward-looking innovation opportunities to meet patient and market needs. #isotope #nuclearmedicine
